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Oxfendazole is recommended as the drug of choice for treating porcine cysticercosis. The drug does not kill brain cysts and
is not registered for use in pigs. Latest its safety in the recommended dose has been questioned. The aim of this study was to
investigate two alternative anthelminthics. The eﬃcacy of praziquantel and ivermectin was compared to oxfendazole In Vitro on
Taenia solium. Cysts of T. solium were isolated from infected pork and incubated in culture media together with the drugs. The
degree of evagination was used as eﬀect measurement and determined after 6 hours. Praziquantel had a half maximal eﬀective
concentration (EC50) of value 0.006 ± 0.001 μg/mL. Ivermectin did not show any impact on the evagination in concentrations
from 0.001 to 30 μg/mL and neither did oxfendazole in concentrations from 0.001 to 50 μg/mL.
1. Introduction
This is a short communication concerning porcine cys-
ticercosis, an infectious disease caused by the larval stage
of Taenia solium. This parasite is a zoonotic tapeworm
transmitted between humans and between humans and
pigs. Cysticercosis is widespread in Latin America, Asia,
and Africa, and due to the link between human neuro-
cysticercosis and epilepsy, control of this disease is now
receiving increasing attention [1]. Single intervention is not
an option against a parasitic infection, which is maintained
in areas with no knowledge about the disease, poor sanitary
conditions, free range management of pigs, and absence
or inadequate meat inspection [2]. However, strategic use
of eﬀective anthelminthics in both humans and pigs is a
realistic component of the short-term control of T. solium.
Several drugs have been tested for porcine cysticercosis
including flubendazole, albendazole, oxfendazole (OXF),
and praziquantel (PZQ). OXF has shown eﬃcacy to kill
the cysts when tested in a single oral dose at 30 mg/kg
[3–6]. Palomares et al. and Garcia-Dominguez et al. have
likewise shown PZQ to be eﬀective, when tested in vitro
[7, 8], and a smaller eﬃcacy is observed when administered
in an oral formulation. The oral administration of OXF
and PZQ is not suitable for free roaming pigs, due to
uncertain dose in the pigs. Ivermectin (IVM) is a widely
used anthelmintic in many cysticercosis endemic regions
and is formulated as a subcutaneous (s.c.) drug, which
is suitable for administration to free roaming pigs. The
eﬀect of IVM against cysticercosis has not previously been
examined in a systematic study, but Perez-Serrano et al. have
reported positive results of IVM treatment against human
cysticercosis in a case study[9]. The objective of this study
was to investigate the eﬃcacy of the three anthelmintics PZQ,
IVM, and OXF when tested in vitro against T. solium cysts.
2. Materials and Methods
Naturally infected pigs (8 to 24 months old) confirmed
positive by tongue examination, were bought at Chibolya
Small Animal Livestock Market in Lusaka, and transported
to the School of Veterinary Medicine at the University
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of Zambia (UNZA), Lusaka, Zambia. At UNZA the pigs
were slaughtered and the carcasses were cut into smaller
pieces. Only cysts with fluid and an intact bladder wall were
collected and washed in phosphate buﬀered saline (PBS)
(Medicago, Sweden, article no. 09-9420-100). Up to 25 cysts
were placed in each petri dish, and drug solution and culture
media were added to yield a final volume at 20 mL, which
was enough to cover 25 cysts. The culture medium consisted
of 50% v/v bovine bile in isotonic sodium chloride (BDH
Chemicals, England, product no. 30123). Bovine bile was
collected from a slaughterhouse in Mazabuka at Turnpike
Abattoir and stored at −20◦C until use.
PZQ (Dr. Ehrenstorfer, Lot nr. 80821, Germany) and
IVM (Dr. Ehrenstorfer, Lot nr. 80715, Germany) were tested
in final concentrations between 0.001 and 30 μg/mL and OXF
(Dr. Ehrenstorfer, Lot nr. 60505, Germany) was tested in final
concentrations between 0.001 and 50 μg/mL. All drugs were
dissolved in 99.9% ethanol and further diluted in distilled
water. The concentration range of ethanol in the final test
samples was 0.0001–2.5%. Positive controls consisted of
20 mL culture media only and were incubated together with
the samples each time. The cysts were incubated for 6 hours
in a Yamato Incubator (Japan) at 37◦C and subsequently
investigated for evagination by visual inspection. Evagination
had occurred, when the bladder wall opened and the neck
and scolex emerged [10]. Evagination as eﬀect measurement
was established based on Sikasunge and coworkers [6].
Prior to the in vitro drug experiments, storage control
studies of the cysts were performed. Freshly isolated cysts
from a pig were divided into four batches. The first batch
was incubated just after slaughtering. The second, third,
and fourth batches were stored at 4◦C in 500 mL bottles,
containing PBS and 100 cysts in each. After one, two, and
three nights, respectively, the evagination of the batches was
examined. Each batch contained 75 cysts equally distributed
in 3 petri dishes. A solvent control study was additionally
conducted, using ethanol at the following concentrations
0.5-1-2-3-4-5%. 75 cysts equally distributed in 3 petri dishes
were used for each concentration in this experiment.
The results from the storage control experiment and
the solvent control experiment were analysed by One-Way
ANOVA followed by Dunnett’s multiple comparison test
(α = 0.01). The observations were expressed as evaginated
cyst in correlation with the positive control (in percentage).
Observations from the three drug experiments were plotted
against log to final drug concentrations. When a relationship
was observed, the data were fitted to a sigmoidal dose-
response curve (variable slope). All graphs and statistical
analysis were made in GraphPad Prism 4.
3. Results
The storage experiment showed that there was no significant
diﬀerence between the cysts ability to evaginate, when
incubated right after slaughter or after one night storage
at 4◦C, whereas the evagination dropped significantly after
2 days (results not shown). Therefore cysts in this study
were used right away or after one night of storage. The
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Figure 1: Percentage evaginated cysts in correlation with positive
control, against the log concentration of praziquantel. The line is
obtained by pooled data from four experiments and fitted to a
dose-response sigmoidal curve (variable slope). The total number
of cysts examined for this praziquantel study was 1803. The error
bars represent standard deviation (S.D).
solvent control study showed no significant diﬀerence in the
cysts ability to evaginate, when incubated in up 5% ethanol,
but the viability of the evaginated cysts was significantly
decreased at 2% ethanol (results not shown).
The eﬃcacy of PZQ is shown in Figure 1. The graph
shows approximately a mirror image of an s-shaped curve,
when using log-transformed data at the x-axis and nonlog-
transformed data at the y-axis, and a straight line is observed
between 20 and 80% eﬀects. The EC50 value was 0.006 μg/mL
± 0.001 μg/mL.
When testing IVM and OXF no significant diﬀerences
from the positive controls were observed at any of the con-
centrations. The eﬃcacy of IVM in concentrations between
0.001 and 30 μg/mL and OXF in concentrations between
0.001 and 50 μg/mL is presented in Figure 2.
4. Discussion
PZQ had an EC50 value of 0.006 ± 0.001 μg/mL on evagi-
nation of T. solium cysts in vitro. IVM and OXF did not
show any impact on evagination from 0.001 to 30 μg/mL
(IVM) and 0.001 to 50 μg/mL (OXF), which leaves PZQ
as the only potent drug against T. solium cysts in this in
vitro test system. The EC50 value of PZQ in this study is
comparable to the data obtained by Garcia-Dominguez et al.,
which showed that PZQ inhibited evagination in vitro in the
concentration range between 3·10−4 and 3·10−3 μg/mL [8].
The PZQ graph in Figure 1 shows an S-shaped curve with
an approximate strait line between 20 and 80% eﬀect. This
shape is comparable to the study by Palomares et al., who
reported an EC50 value of 0.034 μg/mL of PZQ in vitro after
6 hours of incubation [7]. This larger EC50 value could be
due to the slightly diﬀerent eﬀect criterion set by Palomares
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Figure 2: Percentage evaginated cysts in correlation whit positive
control, against the log concentration of ivermectin and oxfenda-
zole. The total number of cysts examined for the ivermectin study
and the oxfendazole study was 750 for both drugs. The error bars
represent standard deviation (S.D). : ivermectin; : oxfendazole.
et al., which is defined as total paralysis of the bladder wall
and loss of cystic fluid [7]. A previous in vivo study likewise
showed that PZQ has an impact on evagination, before the
cysts oxygen consumption is inhibited, which indicates that
PZQ influences evagination prior to cyst death [11].
Neither IVM nor OXF showed any eﬀect on the evagi-
nation in the tested concentration area. Craven et al. have
shown that after s.c. injection of 300 μg/kg IVM in pigs, a
maximal plasma concentration of 9.69 ng/mL occurred [12].
The dose 300 μg/kg almost equals the recommended dose of
IVM for pigs and the plasma level of 9.69 ng/mL is about
3.000 times lower than the highest tested concentration in
this study. Hence it seems unnecessary to test IVM at larger
concentrations.
Although PZQ apparently is an eﬀective drug against
T. solium cysts, the practical administration of PZQ to pigs
is still problematic. In Africa, PZQ is only commercially
available in the form of 600 mg tablets, which is unsuitable
for free roaming pigs. PZQ is available in a gel and pasta
formulation in Europe, which would be a more suitable
formulation. In vivo studies using an oral formulation of
PZQ revealed that it was less eﬀective than oral formulated
OXF [13]. However, further studies testing diﬀerent drug
formulations should be encouraged.
The observed results with OXF in our study fit poorly
with results obtained in vivo [3–5]. In previous studies it
is suggested that although anthelmintic drugs aﬀect the
parasite metabolism and damage the cysts, the death of the
parasite occurs later as a result of direct attack from the host
immune system [4, 14]. It has been demonstrated that it takes
about one month before cysts viability is reduced to a level,
which eﬀectively controls the life cycle of T. solium [4, 6].
The theory is supported by this present study, where the lack
of eﬀect could be explained by the lack of a functional host
immune system in the in vitro settings.
Our study has clearly demonstrated that PZQ but not
OXF or IVM had a significant eﬀect on T. solium cysts in vitro,
but it also has shown that extrapolation from simple in vitro
to in vivo drug eﬃcacy studies is not possible.
Even though no eﬀect of IVM was observed in this study,
the eﬀect in vivo cannot be rejected. More work is needed on
eﬃcacy and eﬀectiveness of anthelminthics against T. solium
in pigs in order to come forward with evidence-based control
recommendations.
Conflict of Interest
None of the authors have any conflict of interest in relation
to the described work.
Acknowledgments
This work was sponsored by ENRECA Health FFU-
fellowship, Klyngemidlerne from the University of Copen-
hagen, and Department of Pharmacology and Pharma-
cotherapy, Faculty of Pharmaceutical Sciences, University of
Copenhagen. The support from the School of Veterinary
Medicine, University of Zambia, is greatly acknowledged.
The authors would also like to thank K. Chengo and E.
Mulenga for their assistance during the dissection work.
References
[1] R. Kraft, “Cysticercosis: an emerging parasitic disease,” Amer-
ican Family Physician, vol. 76, no. 1, pp. 91–96, 2007.
[2] N. C. Kyvsgaard, M. V. Johansen, and H. Carabin, “Simulating
transmission and control of Taenia solium infections using a
reed-frost stochastic model,” International Journal for Para-
sitology, vol. 37, no. 5, pp. 547–558, 2007.
[3] A. E. Gonzalez, N. Falcon, C. Gavidia et al., “Treatment of
porcine cysticercosis with oxfendazole: a dose-response trial,”
Veterinary Record, vol. 141, no. 16, pp. 420–422, 1997.
[4] A. E. Gonzalez, N. Falcon, C. Gavidia et al., “Time-response
curve of oxfendazole in the treatment of swine cysticercosis,”
American Journal of Tropical Medicine and Hygiene, vol. 59, no.
5, pp. 832–836, 1998.
[5] J. Yong, L. Qing-Zhang, and H. Yan-Hong, “Morphological
changes to early stage Taenia solium cysticerci following
oxfendazole treatment,” Veterinary Journal, vol. 165, no. 1, pp.
73–77, 2003.
[6] C. S. Sikasunge, M. V. Johansen, A. L. Willingham III, P. S.
Leifsson, and I. K. Phiri, “Taenia solium porcine cysticercosis:
viability of cysticerci and persistency of antibodies and cys-
ticercal antigens after treatment with oxfendazole,” Veterinary
Parasitology, vol. 158, no. 1-2, pp. 57–66, 2008.
[7] F. Palomares, G. Palencia, R. Pe´rez, D. Gonza´lez-Esquivel,
N. Castro, and H. J. Cook, “In vitro eﬀects of albendazole
sulfoxide and praziquantel against Taenia solium and Taenia
crassiceps cysts,” Antimicrobial Agents and Chemotherapy, vol.
48, no. 6, pp. 2302–2304, 2004.
[8] C. Garcia-Dominguez, D. Correa, M. T. Rabiella, and A.
Flisser, “Praziquantel treatment of muscle Taenia solium
cysticercosis. 4. reversible in vitro eﬀect,” Parasitology Research,
vol. 77, no. 8, pp. 691–696, 1991.
[9] J. Perez-Serrano, C. Grosman, M. A. Urrea-Paris, G. Denegri,
N. Casado, and F. Rodriguez-Caabeiro, “Depolarization of the
tegument precedes morphological alterations in Echinococcus
4 Journal of Parasitology Research
granulosus protoscoleces incubated with ivermectin,” Para-
sitology Research, vol. 87, no. 10, pp. 804–807, 2001.
[10] T. Rabiela, Y. Hornelas, C. Garcı´a-Allan, E. Rodrı´guez-del-
Rosal, and A. Flisser, “Evagination of Taenia solium cysticerci:
a histologic and electron microscopy study,” Archives of
Medical Research, vol. 31, no. 6, pp. 605–607, 2000.
[11] A. Flisser, D. Gonzalez, M. Shkurovich et al., “Praziquantel
treatment of porcine brain and muscle Taenia solium cys-
ticercosis. 1. radiological, physiological and histopathological
studies,” Parasitology Research, vol. 76, no. 3, pp. 263–269,
1990.
[12] J. Craven, H. Bjørn, D. R. Hennessy, and C. Friis, “The
eﬀects of body composition on the pharmacokinetics of
subcutaneously injected ivermectin and moxidectin in pigs,”
Journal of Veterinary Pharmacology and Therapeutics, vol. 25,
no. 3, pp. 227–232, 2002.
[13] A. E. Gonzales, H. H. Garcia, R. H. Gilman et al., “Eﬀective,
single-dose treatment of porcine cysticercosis with oxfenda-
zole,” American Journal of Tropical Medicine and Hygiene, vol.
54, no. 4, pp. 391–394, 1996.
[14] A. Torres, A. Plancarte, A. N. M. Villalobos, A. S. Aluja, R.
Navarro, and A. Flisser, “Praziquantel treatment of porcine
brain and muscle Taenia solium cysticercosis. 3. eﬀect of 1-day
treatment,” Parasitology Research, vol. 78, no. 2, pp. 161–164,
1992.
